Investors splash £100m on robotic process automation vendor in hopes RPA holds up in wake of COVID-19

Cash-flingers see dollars through a Blue Prism


Purveyor of software robots, Blue Prism, has hired a new CEO and bagged £100m in funding, proof of market confidence in the technology concept in the face of strong economic headwinds.

Far from dampening interest in robotic process automation, the field in which Blue Prism specialises, the COVID-19 pandemic and subsequent global lockdowns are tempting investors to put some money into the area.

Blue Prism, which counts Lloyds Banking Group and Jaguar Land Rover among its customers, said the funding came from new and existing investors, and will be used to protect the company's balance sheet during a period of uncertainty for the wider economy, allowing spending on technology development.

It also took the opportunity to confirm veteran AI exec Jason Kingdon, as the new CEO of Blue Prism, replacing co-founder Alastair Bathgate, who is set to step down at the end of April.

"The capital raised positions us as a strong partner to our enterprise customers as they increasingly look to securely scale beyond a simple proof of concept while leveraging leading-edge AI and cognitive capabilities," said Kingdon, who continues as executive chairman.

Marc Hardwick, research director at analyst firm TechMarketView, said the COVID-19 lockdowns could see accelerated adoption of digital and automation technologies. "Anecdotally, we have already seen over the last few weeks rapid adoption of RPA in a wide range of industries from healthcare to insurance, as organisations get to grips with the challenges of COVID-19 and the lockdown."

Blue Prism said its customer Leeds Building Society has expanded its use of RPA to help cope with the huge increase in mortgage deferral requests, for example.

Other RPA firms have been quick to point out that automating mundane or repetitive tasks may free up time to help people work remotely and become more flexible in response to the challenges the novel coronavirus presents.

UiPath, a rival to Blue Prism in the RPA market, said The Mater Misericordiae Hospital in Dublin is using its technology to help reduce the time taken to process COVID-19 testing kits. RPA also reduces the administrative strain placed upon its Infection Prevention and Control Department, freeing up nurses' time previously spent on paperwork.

In January, Blue Prism reported [PDF] an 83 per cent hike in revenue to £101m for the year ended 31 October 2019 and boosted its customer base by 73 per cent from the previous year to 1,677 global enterprise accounts. The company's earnings before interest, tax, depreciation and amortisation for the year, however, showed a loss of £71.9m, after adjusting for share-based payments, up from a loss of £21.6m the year before. This didn't put investors off at the time; they also chucked £100m at the firm in 2019.

To put that in context, in 2017 US RPA company UiPath was valued at $70m, but just a year later, this had shto up to $3bn on the back of a $225m Series C funding round. It sucked up $568m in a D-round last year, valuing the firm at $7bn.®

Similar topics


Other stories you might like

  • AI tool finds hundreds of genes related to human motor neuron disease

    Breakthrough could lead to development of drugs to target illness

    A machine-learning algorithm has helped scientists find 690 human genes associated with a higher risk of developing motor neuron disease, according to research published in Cell this week.

    Neuronal cells in the central nervous system and brain break down and die in people with motor neuron disease, like amyotrophic lateral sclerosis (ALS) more commonly known as Lou Gehrig's disease, named after the baseball player who developed it. They lose control over their bodies, and as the disease progresses patients become completely paralyzed. There is currently no verified cure for ALS.

    Motor neuron disease typically affects people in old age and its causes are unknown. Johnathan Cooper-Knock, a clinical lecturer at the University of Sheffield in England and leader of Project MinE, an ambitious effort to perform whole genome sequencing of ALS, believes that understanding how genes affect cellular function could help scientists develop new drugs to treat the disease.

    Continue reading
  • Need to prioritize security bug patches? Don't forget to scan Twitter as well as use CVSS scores

    Exploit, vulnerability discussion online can offer useful signals

    Organizations looking to minimize exposure to exploitable software should scan Twitter for mentions of security bugs as well as use the Common Vulnerability Scoring System or CVSS, Kenna Security argues.

    Better still is prioritizing the repair of vulnerabilities for which exploit code is available, if that information is known.

    CVSS is a framework for rating the severity of software vulnerabilities (identified using CVE, or Common Vulnerability Enumeration, numbers), on a scale from 1 (least severe) to 10 (most severe). It's overseen by First.org, a US-based, non-profit computer security organization.

    Continue reading
  • Sniff those Ukrainian emails a little more carefully, advises Uncle Sam in wake of Belarusian digital vandalism

    NotPetya started over there, don't forget

    US companies should be on the lookout for security nasties from Ukrainian partners following the digital graffiti and malware attack launched against Ukraine by Belarus, the CISA has warned.

    In a statement issued on Tuesday, the Cybersecurity and Infrastructure Security Agency said it "strongly urges leaders and network defenders to be on alert for malicious cyber activity," having issued a checklist [PDF] of recommended actions to take.

    "If working with Ukrainian organizations, take extra care to monitor, inspect, and isolate traffic from those organizations; closely review access controls for that traffic," added CISA, which also advised reviewing backups and disaster recovery drills.

    Continue reading

Biting the hand that feeds IT © 1998–2022